Lower drug dose after transplant may cut infections without losing protection

NCT ID NCT06001385

Ongoing Disease control Sponsor: Center for International Blood and Marrow Transplant Research Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 05, 2026 · Updated 13 times

Summary

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 313 adults with various blood cancers will take part. The goal is to improve recovery and survival after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
Barnes Jewish Hospital / Washington University

St Louis, Missouri, 63110, United States
City of Hope

Duarte, California, 91010, United States
Colorado Blood Cancer Institute at Presbyterian St. Luke's

Denver, Colorado, 80218, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University

Atlanta, Georgia, 30322, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Greenbaum Cancer Center University of Maryland

Baltimore, Maryland, 21201, United States
Honor Health

Scottsdale, Arizona, 85258, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Rochester, Minnesota, 55902, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center - Adults

New York, New York, 10065, United States
Methodist Hospital San Antonio

San Antonio, Texas, 78229, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ohio State Medical Center

Columbus, Ohio, 43210, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
St. David's South Austin Medical Center

Austin, Texas, 78704, United States
Stanford University

Stanford, California, 94305, United States
The Center for Bone Marrow Transplantation at Geisinger

Danville, Pennsylvania, 17822, United States
TriStar Centennial

Nashville, Tennessee, 37203, United States
Tufts University

Boston, Massachusetts, 02155, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of California San Francisco

San Francisco, California, 94158, United States
University of Miami Sylvester Cancer Center

Miami, Florida, 33136, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Health System

Charlottesville, Virginia, 22908, United States

Conditions

Explore the condition pages connected to this study.

ACUTE LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA LYMPHOMA MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM PRO-LYMPHOCYTIC LEUKEMIA PRO-LYMPHOCYTIC LEUKEMIA